A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...
News Medical on MSN1d
New treatment combination improves outcomes for small cell bladder and prostate cancer patientsA research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Foll ...
Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy ...
AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...
At ESMO, oncologists got their first look at the results of the EV-302/KEYNOTE-A39 trial of MSD’s PD-1 inhibitor Keytruda (pembrolizumab ... with metastatic bladder cancer,” said Dr Apolo ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback